Frontlight ResearchEarly access
Taking people in United StatesNo phase
Studies ublituximab safety in older adults with relapsing multiple sclerosis
Observes infection rates in older adults with relapsing multiple sclerosis receiving ublituximab.
Key facts
- Who runs it
- Neurology Center of New England P.C.
- Where
- Foxborough, United StatesSee the site
- Trial code
- Registry title
- A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 13 Aug 2024
- Expected to end
- 30 Sept 2027
- Type of study
- Observational
- Treatments tested
- Ublituximab
- Record updated
- 18 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for older adults aged 55-80 with relapsing multiple sclerosis who are starting ublituximab or started it within the last 6 months.
- Age
- 55-80 years old
- Sex
- All sexes can join.
- Disease stage
- Relapsing forms of multiple sclerosis (RMS), diagnosed by the 2017 Revised McDonald criteria.
- Earlier treatment
- Starting ublituximab soon, or first dose given no more than 6 months before joining, as set by the local label.
Main reasons for not taking part
- Taking part in another interventional MS trial right now
- First ublituximab dose more than 6 months ago
- Past life-threatening infusion reaction to an anti-CD20 therapy
- Ongoing serious viral, bacterial or fungal infection needing long-term treatment
- Repeated infections in the 6-12 months before starting ublituximab
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Signed informed consent
- Aged 55-80 years old
- Diagnosis of RMS according to the 2017 Revised McDonald criteria
- Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label
Who cannot take part
- Received initial dose of ublituximab more than 6 months prior to study entry
- Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab
- History of life-threatening infusion reaction on any anti-CD20 therapy
- Active participation in an interventional clinical trial for MS
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 80 years old?
Where in United States
- Neurology Center of New England P.C.Foxborough, United StatesContact: Rachel ODonnellTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Treatments tested
- Ublituximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
- Plain-language title
- Studies ublituximab safety in older adults with relapsing multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06681623, who can take part
- Record updated
- 18 November 2024